Does Rallies show 13F holders for SLDB?

Yes. Rallies tracks hedge fund and 13F ownership data for SLDB, including fund names, share counts, latest tracked quarter, and position changes when available.

Is SLDB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SLDB. It does not provide personalized investment advice.

SLDB (Solid Biosciences Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Solid Biosciences Inc. Common Stock (SLDB) is a publicly traded Healthcare sector company. As of May 21, 2026, SLDB trades at $6.47 with a market cap of $640.91M and a P/E ratio of -3.19. SLDB moved +6.58% today. Year to date, SLDB is +21.39%; over the trailing twelve months it is +119.32%. Its 52-week range spans $2.41 to $8.87. Analyst consensus is strong buy with an average price target of $17.33. Rallies surfaces SLDB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns SLDB stock?

Hedge funds tracked by Rallies that own SLDB include Redmile Group and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Solid Biosciences Inc. Common Stock.

SLDB Key Metrics

Key financial metrics for SLDB
Metric	Value
Price	$6.47
Market Cap	$640.91M
P/E Ratio	-3.19
EPS	$-1.99
Dividend Yield	0.00%
52-Week High	$8.87
52-Week Low	$2.41
Volume	974.73K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-174.32M
Gross Margin	0.00%

Top Hedge Funds Holding SLDB

Redmile Group holds 2.01M shares of SLDB, changed +8.13% as of Mar 31, 2026.
Panagora Asset holds 91.09K shares of SLDB, changed -59.83% as of Mar 31, 2026.

Latest SLDB News

Solid Biosciences Doses First Phase 3 Duchenne Participant, Holds $380.7M Cash Runway — May 12, 2026
Solid Biosciences Secures $240M Funding, Targets April Phase 3 Duchenne Dosing — Mar 19, 2026
Solid Biosciences Achieves 91% Microdystrophin Expression, 44% eMHC Reduction in Trial — Mar 11, 2026
Solid Biosciences Shares Jump 12% on Gene Therapy Approval Tailwind — Mar 9, 2026
FDA Grants Orphan Drug Status to Solid Biosciences’ SGT-212 and Doses First FALCON Patient — Jan 14, 2026

Recent SLDB Insider Trades

Cumbo Alexander sold 16.64K (~$96.92K) on Feb 18, 2026.
Hanrahan Jessie sold 4.13K (~$24.07K) on Feb 18, 2026.
Ganot Ilan sold 2.66K (~$15.48K) on Feb 18, 2026.

SLDB Analyst Consensus

11 analysts cover SLDB: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.33.

Common questions about SLDB

Who owns SLDB stock?: Hedge funds tracked by Rallies that own SLDB include Redmile Group and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Solid Biosciences Inc. Common Stock.
Does Rallies show 13F holders for SLDB?: Yes. Rallies tracks hedge fund and 13F ownership data for SLDB, including fund names, share counts, latest tracked quarter, and position changes when available.
Is SLDB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SLDB. It does not provide personalized investment advice.